Thomas Gerlach PhD – Pharma professional with more than 30 years of experience in biopharmaceuticals and venture capital, who worked in big multinational companies like Knoll and Novartis in Germany and Switzerland, but also in successful startups like Actelion, (Switzerland and Brazil), early startup like Biozeus (Brazil) and in venture capital in life science. During his career, he worked in drug development, leading global teams, but also in commercial and operational functions, as general manager of Actelion Brazil. During his 9 years in venture capital he identified investment opportunities in biopharmaceuticals, diagnostics and medical equipment and supported portfolio companies on the operational as well as board level. Currently, Thomas is Chief Strategic Officer of Pannex Therapeutics Inc, a New York based biopharmaceutical company, developing, first in class pannexin 1 channel blockers, targeting chronic pain and other indications. Thomas holds an PhD in Biology and an BA in chemistry, from the university of Mainz (Germany) and has spent 3 years as researcher at Michigan State University.